drug_type
RELEVANT_DRUG
intervention_type
Biological (genetically modified cellular therapy; TCR-engineered T cells)
drug_description
Gene-modified adoptive T-cell therapy in which donor T cells are lentivirally transduced to express an EBV-specific, HLA-A*02:01/11:01/24:02–restricted T-cell receptor; upon recognizing EBV peptides presented on HLA class I, the engineered T cells kill EBV-infected cells and secrete cytokines.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Donor-derived T cells are lentivirally transduced to express an EBV-specific, HLA-A*02:01/11:01/24:02–restricted T-cell receptor. After infusion, they recognize EBV peptides presented on HLA class I on infected cells, activate via TCR signaling, and mediate cytotoxic killing (perforin/granzyme) with cytokine secretion to eliminate EBV-infected cells and restore antiviral immunity.
drug_name
EBV-TCR-T cells
nct_id_drug_ref
NCT06119256